Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Roy S. Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Publikováno v:
Journal of Clinical Oncology. 41:1830-1840
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Publikováno v:
Journal of Clinical Oncology. 37:1863-1867
Autor:
Benjamin J. Solomon, Todd Michael Bauer, Enriqueta Felip, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Konstantin K. Laktionov, Fiona Helen Blackhall, Elisa Dall’O, Anna Polli, Francesca Toffalorio, Tony S. K. Mok
Publikováno v:
Journal of Clinical Oncology. 40:9069-9069
9069 Background: Lorlatinib, a brain-penetrant, third generation ALK tyrosine kinase inhibitor (TKI), demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs crizotinib in a phase 3 study in
Autor:
Sanjay Popat, Enriqueta Felip, Edward S. Kim, Filippo de Marinis, Byoung Chul Cho, Martin Wermke, Adrianus De Langen, Roberto Ferrara, Stephan Kanzler, Fabiana Letizia Cecere, Domenico Galetta, Dae Ho Lee, Vanesa Gregorc, Ana Rodrigues, Christian Britschgi, Ahmadur Rahman, Diana Ndunda, Johannes Noe, Danny Lu, Benjamin Besse
Publikováno v:
Journal of Clinical Oncology. 40:TPS9159-TPS9159
TPS9159 Background: RET gene fusions have been identified as oncogenic drivers in multiple tumor types, including 1–2% of non-small cell lung cancer (NSCLC). Pralsetinib is a potent, selective RET inhibitor, approved in the US and EU for the treatm
Autor:
Makoto Nishio, Jie Zhang, Chetachi Emeremni, Myung-Ju Ahn, Lucio Crinò, David R. Spigel, Tony Mok, Toyoaki Hida, Enriqueta Felip, Filippo de Marinis, Massimiliano Quadrigli, Giorgio V. Scagliotti, Alice T. Shaw, Fabrice Branle, Heather A. Wakelee, Harry J.M. Groen
Publikováno v:
Journal of Clinical Oncology, 34(24), 2866-2878. AMER SOC CLINICAL ONCOLOGY
Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and with or without prior therapy with an inhibitor of the ALK protein. Data are pre
Autor:
Alvaro Leone, Filippo de Marinis, Rita Gasbarra, Paolo Graziano, Giuseppe Pelosi, Stefano De Santis, Bruno Gori, Rita Migliorino
Publikováno v:
Journal of Clinical Oncology. 33:e115-e118
Autor:
Monette Villalobos, Filippo de Marinis, David R. Spigel, Dolores Isla, Ida Berglin Enquist, Simonetta Mocci, Yu Deng, Jacek Jassem, Tibor Csőszi, See Phan, Gongyan Chen, Xiaohui Wen, Toyoaki Hida, Hina Patel, Jacques Cadranel, Diego Cortinovis, Giuseppe Giaccone, Roy S. Herbst, Hiroshi Kuriki, Konstantinos N. Syrigos
Publikováno v:
Journal of Clinical Oncology. 38:e21623-e21623
e21623 Background: IMpower110 evaluated atezo mono in PD-L1–selected, chemo-naive patients (pts) with nonsquamous (nsq) or squamous (sq) NSCLC. At the interim analysis, IMpower110 met its primary OS endpoint, with a statistically significant and cl
Autor:
Roy S. Herbst, Hiroshi Kuriki, Megan Chen, Lucia Bonomi, See Phan, Ioannis Boukovinas, Giuseppe Giaccone, Filippo de Marinis, Cristina-Marinela Oprean, David R. Spigel, Kimberly Komatsubara, Young-Chul Kim, Simonetta Mocci, Jacek Jassem, Takayasu Kurata, Yu Deng, Yvonne Summers, Aleksandra Szczesna
Publikováno v:
Publons
9594 Background: IMpower110 (NCT02409342) evaluated atezo (anti–PD-L1) monotherapy as 1L treatment in PD-L1–selected patients (pts) with metastatic NSCLC and met its primary endpoint with statistically significant and clinically meaningful OS ben
Autor:
Paolo Bidoli, William J. John, Carla Visseren-Grul, Filippo de Marinis, Mircea Dediu, Symantha Melemed, Martin Reck, Olivier Molinier, Jesus Corral, Cesare Gridelli, Jean-Louis Pujol, Tarini Prasad Sahoo, Nadia Chouaki, Luis Paz-Ares, Eckart Laack, Mike Thomas, Annamaria Zimmermann
Publikováno v:
Journal of Clinical Oncology. 31:2895-2902
Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and upd